[144] Legend Biotech Corp SEC Filing

Rhea-AI Filing Summary

Legend Biotech Corp (LEGN) reported a Form 144 notice showing proposed sale of 1,357 American Depositary Shares through Fidelity Brokerage, listed on NASDAQ, with an aggregate market value of $46,111.81 and approximately 367,298,315 shares outstanding. The shares were acquired on 09/19/2025 through restricted stock vesting as compensation and the planned sale date is 09/23/2025. The filer also reported three prior ADS sales in June–July 2025 totaling 38,220 shares for gross proceeds of $1,505,975.55. The filing represents a routine insider sale report under Rule 144.

Positive

• Disclosure compliance: The filer provided required Rule 144 details including broker, share amounts, and sale dates
• Source specified: Securities were acquired via restricted stock vesting, clarifying they are compensation-related shares

Negative

• Insider sales reported: Three prior sales in June–July 2025 totaled 38,220 ADSs for $1,505,975.55, which may attract investor attention
• Concentration of recent sales: Multiple dispositions within a short period could prompt monitoring for further insider selling

Insights

Financial Analyst

TL;DR: Insider sold recently vested shares; disclosed past month sales totaling ~$1.51M; appears routine and non-material to market cap.

The notice shows the proposed sale of 1,357 ADSs received via restricted stock vesting, with contemporaneous prior sales of 38,220 ADSs yielding about $1.506 million in gross proceeds. Given the issuer's reported outstanding ADSs of 367.3 million, these transactions represent a very small percentage of the float and are unlikely to materially impact share supply or valuation. The filing complies with Rule 144 disclosure requirements and identifies the broker and sale timing clearly.

Corporate Governance Expert

TL;DR: Disclosure is timely and specifies compensation origin; clustered sales in recent months warrant routine monitoring but show no clear governance red flag.

The form specifies the securities were acquired via restricted stock vesting and to be sold through an identified broker, which aligns with expected insider reporting practices. Multiple sales across June–July and the proposed September sale indicate ongoing monetization of vested compensation rather than a single large disposition. No statements in the filing indicate undisclosed material information. Stakeholders may track future filings for patterns, but current filings present routine governance disclosure.

09/23/2025 - 03:13 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1357	46111.81	367298315	09/23/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	09/19/2025	Restricted Stock Vesting	Issuer			1357	09/19/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ying Huang 2101 Cottontail Lane Somerset NJ 08873	American Depositary Shares	06/24/2025	11810	408600.02
Ying Huang 2101 Cottontail Lane Somerset NJ 08873	American Depositary Shares	06/25/2025	12119	408652.68
Ying Huang 2101 Cottontail Lane Somerset NJ 08873	American Depositary Shares	07/23/2025	15291	688722.85

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Legend Biotech (LEGN) report on the Form 144?

The filer reported a proposed sale of 1,357 ADSs valued at $46,111.81, acquired on 09/19/2025 via restricted stock vesting, with a planned sale date of 09/23/2025.

How many shares has the insider sold recently according to the filing?

The filing lists three prior sales on 06/24/2025, 06/25/2025, and 07/23/2025 totaling 38,220 ADSs for gross proceeds of $1,505,975.55.

Were the securities being sold acquired as compensation or purchase?

Yes, the 1,357 ADSs to be sold were acquired through restricted stock vesting and the payment nature is listed as compensation.

Through which broker will the proposed sale occur?

The proposed sale is through Fidelity Brokerage Services LLC, located at the address provided in the filing.

What proportion of outstanding shares does the proposed sale represent?

The filing lists 367,298,315 shares outstanding; the proposed sale of 1,357 ADSs is an immaterial fraction of that total.